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Introduction
Aptamers are short, single-stranded nucleotide sequences that can bind to a
target molecule with high specificity, allowing for a robust range of industrial,
diagnostic, clinical, and therapeutic applications. Aptamers have been the
subject of more than 144,000 papers to date. There has been a growing
concern that discrepancies in the reporting of aptamer research limit the
reliability of these reagents for research and other applications.
We first noted the misinterpretation of an 80-mer RNA anti-lysozyme aptamer.
Subsequent works not only altered the aptamer sequence, but also truncated
the aptamer. We hypothesized that the alteration of the anti-lysozyme aptamer
may not have been an isolated event.
These observations noting inconsistencies in the use of the RNA anti-lysozyme
aptamer served as an impetus for our systematic review of the reporting of
aptamer sequences in the literature. Our purpose was to determine the depth
and breadth of aptamer sequence infidelity throughout the literature.

Results
Our detailed examination of literature citing the RNA anti-lysozyme aptamer
revealed that 93% of the 61 publications reviewed reported unexplained
altered sequences with 96% of those using DNA variants.
We expanded our search to analyze each of the ten most cited aptamers,
where we discovered that 41% of the 780 aptamer publications we reviewed
reported unexplained sequence alterations.

Discussion
The figure below illustrates the results of our anti-lysozyme aptamer analysis,
the methodology of which was used throughout our investigation. Clones were
analyzed for fidelity to the original sequence, alterations were described and
documented, and a phylogeny detailing the evolution of sequence alterations
over time was constructed.

Overall, only 59% of the 780 publications our group reviewed correctly reported
the aptamer sequence(s) and/or explained sequence alterations, while 41%
contained one or more in silico sequences that were categorized as
unexplained. We identified 120 novel sequences that according to our criteria
were not adequately explained. 39% of these 120 sequences identified
contained deletions, 35% contained 5’ or 3’ unexplained additions, 8% did not
provide the sequence at all, 7% contained insertions, 7% contained
substitutions, and less than 2% contained core binding sequence
misidentifications, inversions, the complementary sequence, or an entirely
different sequence.

The figure below illustrates the distribution of sequence alterations throughout
the papers our group reviewed, including further stratification into high and low
apparent error phylogenies.

Methods
An anti-lysozyme aptamer in 2001 had been reported to ‘mutate’ in the
literature over time, and we therefore used this aptamer as a starting point for
establishing a broader methodology.
We first identified an originating aptamer and then examined the literature
citing the sequence of this originating aptamer. In cases where multiple clones
selected in a paper were used in the literature, all clones were examined as
“root” aptamers. Unexplained sequence alterations were again categorized,
and a phylogeny was constructed to document the evolution of these
alterations.
Following our analysis of the anti-lysozyme aptamer, a review of aptamers
against the ten most used targets was performed. This review systematically
sampled the aptamer literature, spanning years, researchers, labs, and
locations.

In all, 780 publications from 23 originating/root aptamers were reviewed using
this standardized sampling methodology.
Of those reports that varied from the original RNA aptamer, the papers were
reviewed to ascertain if the reported alterations were adequately described,
omitted, or unexplained. Sequence alterations found include deletions,
insertions, and/or substitutions. Samples ranged from 9-171 publications,
although we aimed to acquire at least 50 papers for each phylogeny.

Conclusion
Our literature search bolsters the argument that the field of aptamer research is
experiencing considerable inconsistencies in aptamer sequence reporting.
Further, these widespread inconsistencies warrant the application of
collaborative, evidence-based aptamer publication guidelines to improve
reproducibility and consistency within the literature.

In the future, collaborative evidence-based aptamer validation guidelines
should be encouraged by journals, including a checklist for the peer review
process. Ultimately, we believe that the standardization of aptamer publication
guidelines and increased availability of raw data will lead to a more open,
nuanced discussion of the data presented, and greater success in the
translation of aptamer research to the clinic and industry.

Our findings can be used as a starting point for building better practices in
author submissions and publication standards, the rigor, and reproducibility of
aptamer research.

At a minimum, we suggest that three categories of information should be
required in aptamer publications: 1. complete sequence and secondary
structure information (i.e., mFOLD), including consistent sequence identifiers;
2. detailed descriptions of binding and experimental conditions; and 3.
extensive use of negative and positive controls, for both aptamers and targets.

